RT Journal Article
SR Electronic
T1 Effect of non-drug Intervention on Cognitive Function and Blood Sugar Control of Type 2 Diabetes patients with Mild Cognitive Impairment: A Meta-analysis Protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.19.24314026
DO 10.1101/2024.09.19.24314026
A1 Wenhao, Su
A1 Hairong, Jia
A1 Yanru, Wang
A1 Luo, Yang
A1 Xueling, Li
A1 Jiaqi, Zhang
A1 Zhaoyang, Wei
A1 Pepertual, Tsikwa
YR 2024
UL http://medrxiv.org/content/early/2024/09/22/2024.09.19.24314026.abstract
AB This study aims to assess non-drug therapies’ safety and effectiveness on cognitive function and blood glucose control of type 2 diabetes with mild cognitive impairment (T2DM-MCI) patients in randomized controlled trials by meta-analysis, providing constructive evidence for non-drug treatment decision-making. The system review plan will strictly follow the Systematic Review and Meta-Analysis Protocols entry for reporting. PubMed, EMBASE, Cochrane Library, CINAHL, Web of Science, CNKI, WANGFANG Database, and SinoMed will be systematically searched with Chinese and English language restrictions, and all randomized controlled trials comparing non-drug treatment with usual care or no intervention or placebo to study cognitive impairment in T2DM-MCI patients will be included. We will also manually search for cited literature. Our primary outcomes are cognitive function and blood sugar control. The risk of bias will be assessed for all studies using the Cochrane risk-of-bias tool (RoB 2) for Systematic Review of Intervention-version 5.1.0. Where possible, meta-analysis using random-effects models will be performed, otherwise, a qualitative summary will be provided. We will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) guidelines. This meta-analysis compares the efficacy of non-drug interventions for mild cognitive impairment in type 2 diabetes mellitus. It will provide reliable evidence for patients, clinicians, and researchers.The methodological protocol was in registered in the PROSPERO (CRD 42024496248).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.